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 Pulmonary Hypertension (PH) is associated with the increase in blood pressure in 
the lung vasculature leading to fatigue, dizziness, chest pain and ultimately death. The 
general prognosis is survival of 2-3 years and then death caused by right ventricular failure. 
Research is focused on developing therapeutic methods to cure this disease.  
 Recent studies showed that the Resistin and Resistin-like molecule (RELM) family 
of proteins (adipocyte-specific hormone) are involved in the vascular remodeling and 
cardiac dysfunction seen in animal and human pulmonary arterial hypertension (PH). 
These results suggested human-resistin (hresistin) and human-RELM  (hRELM ) are 
important for the etiology of human PH and are potential biomarkers and therapeutic 
targets for this disease. This led to development of a series of human antibodies that target 
distinct and common epitopes of hresistin and hRELM  by the members of Dr. Roger 
Johns’ research group. My goal is to create 3-d models of these antibodies in complex with 
hresistin + hRELM  to gain insight into their functions. 
 Using homology modelling techniques such as SWISS-MODEL and MODELLER, 
I predicted the three-dimensional structures of hresistin and hRELM , using the 
crystallographic structures of mouse-resistin and mouse-RELM . Using RosettaAntibody 
protocol, I modelled the three-dimensional structures of a series of 32 human antibody 
sequences designed specifically to target hresistin and hRELM . These models confirmed 
the antibody’s stability and suitability. The predicted structures of these 32 antibodies 
validated that they were designed conforming to the standard structural parameters of 
naturally occurring human antibodies. Experimental studies showed that hresistin and 
hRELM  exist in multimer states but that the monomer form is the most functional. 
Therefore, using the SnugDock protocol in Rosetta, I docked each of the antibodies to 
hresistin and hRELM  monomeric forms.  From the docking results, I identified the most-
likely antibody-antigen docked state using model energies. From the docked structure of 
each antibody-antigen complex, I extracted the epitope regions of hresistin and hRELM . 




region of hresistin and strongly to the tail region of hRELM . The docking results of 
antibody AntiRes-13 also validated its corresponding antigen binding experiments. Out of 
the set of 32 antibodies, antibody AntiRes-2, 3, 9, 11 and 41 also showed positive binding 
affinities to the antigens. In the models, AntiRes-β binds hresistin at the head and hRELM  
at the head. Antibody AntiRes-3 binds the tail region of hresistin and head region of 
hRELM . Antibodies AntiRes-9 and AntiRes-11 bind to the head regions of both hresistin 
and hRELM  whereas AntiRes-41 prefers to bind the tail region of both antigens. This 
project gives insight into design for potential therapeutic applications for curing PH.   
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I. Pulmonary Hypertension 
Pulmonary Hypertension (PH) is a severe disease of the lung vasculature 
leading to right heart failure and death. It is defined as an increase in blood 
pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries 
which leads to shortness of breath, dizziness, fainting and other symptoms 
ultimately causing death[1-8]. There is no currently cure for this disease, and 
most current therapies provide only limited relief. According to latest 
classification there are six different types of pulmonary hypertension, all 
leading to a common endpoint[4]. 
Pulmonary arterial hypertension is caused due to the narrowing of the blood 
vessels connected to or within the lungs[2,4]. This makes it difficult for the 
heart to pump blood to the lungs. Over time the blood vessels develop fibrosis 
which further increases the blood pressure. The increased workload of the 
heart causes hypertrophy of the right ventricle ultimately causing right heart 
failure. As the blood flowing through the lungs decreases, the left side of the 
heart receives less blood. This blood may also carry less oxygen than normal. 
Therefore, it becomes harder and harder for the left side of the heart to pump 
to supply sufficient oxygen to the rest of the body. The general prognosis is 








II. Resistin and RELM proteins 
Resistin initially was identified in rodents as adipose-tissue-specific-
secretory-factor (ADSF) which was associated with diabetes[19-22]. It was 
observed that resistin played a role in glucose metabolism and insulin 
resistance. Circulating levels of resistin in the blood of mice were down 
regulated by anti-diabetic drugs and experimental modification led to changes 
in the blood glucose and insulin function[19-22]. During the characterization, of 
human resistin it was observed that it expresses in macrophages rather than in 
the adipose tissues. Also, the levels of the circulating resistin are associated 
with inflammation[21,22].  
During initial characterization of resistin, additional resistin-like genes were 
identified[21,22]. Currently apart from resistin, three other members were 
observed in mice which are RELMα, RELM  and RELM . One more member 
was observed in humans which is RELM [19-20]. 
Proteins in the resistin family have a unique structure with no known 
homology to any other proteins. Both human and rodent variants contain 
between 105 and 117 amino acids with notable interspecies (33%-59%) and 
intra-species (21-51%) homology[19-22]. The common feature of these proteins 
is the presence of five disulfide bonds formed by cysteine signature motif 
(CX11CX8CXCX3CX10CXCXCX9CC) in the c-terminal part of the protein 
that forms a monomer consisting of a globular head and a helical tail[19]. 
During the process of investigating the function of human resistin using 




that hresistin and hRELM  exist as three species: monomer of a low-
molecular-weight (LMW) at approx. 13kDa, a medium-molecular weight 
(MMW) dimer of  26kDa formed by a disulphide bond between the terminal 
tail of two monomers, and a high-molecular-weight hexamer at  50kDa made 
up of three dimers twisted together[14-16]. The formation of intermolecular 
disulphide bonds between cysteine 22 in human resistin is essential for resistin 
multimerization and secretion. Different molecular isomers of human resistin 
may exhibit differences in bioactivity, like human adiponectin, another family 
of proteins with similar structure to resistin. 
 
III. Association of the protein with PH 
The resistin-like molecule (RELM) family of proteins comprises pleiotropic 
cytokines critically involved in the vascular remodeling and cardiac 
dysfunction seen in animal and human PH. Dr. Roger Johns laboratory 
discovered the RELM family of proteins in PH lung as a “hypoxia-induced 
mitogenic factor (HIMF)”[9-14]. They demonstrated that these proteins have 
pro-inflammatory, proliferative, vasoconstrictive, and chemokine actions and 
the ability to induce the vascular remodeling and hemodynamic changes of 
PH in rodent models (gain of function)[9-14]. Inhibition of this pathway by 
adeno-associated virus (AAV) shRNA against HIMF or knockout of HIMF 
prevents the development of hypoxia-induced PH (loss of function)[15-17]. 
Their subsequent work further validated human resistin (hresistin) and human 
RELM  (hRELM ) as therapeutic targets for human PH. They found that 
hresistin and hRELM  were upregulated in the lung hypertrophic vasculature 




RELM proteins induce cardiac hypertrophy, cardiac fibrosis, and 
dysfunctional sarcomere shortening[18-22]. They identified specific 
polymorphisms in hresistin and hRELM  associated with development of PH 
within patient population, some of which correlate with serum resistin level 
and with biochemical and clinical markers of heart failure. These results 
suggested that hresistin and hRELM  are mechanistically important to the 
etiology of human PH and may serve as potential biomarkers and therapeutic 
targets for this disease. 
IV. Goals of my thesis 
My thesis work is a collaboration with members of Dr. Roger John’s 
laboratory from Johns Hopkins School of Medicine who provided the 
experimental support necessary to compare with my computational models. 
The main goals of my thesis are as follows: 
i. Predict the three-dimensional structures of hresistin and 
hRELMβ: As there are no crystallographic structures of the 
proteins, it was necessary to understand the structural 
significance of these proteins and the role their various multimer 
form plays.  
ii. Model structures of human antibodies: Using a human SCFV 
library, 32 human IgG1 antibody sequences were selected 
specifically to target hresistin and hRELM . I modelled all the 
32 antibodies sequences using RosettaAntibody. The models of 
these antibodies were usedto estimate their binding affinities and 
epitopes. 
iii. Docking human antibodies with hresistin and hRELMβ: 




target antigens. I predicted the best docked state of each of the 
antibody-antigen complexs which I further analyzed to 
determine the potential epitope regions of the target antigens.  
 
The results from my work are a step towards the goal of building a successful 
therapeutic model for curing Pulmonary Hypertension. My project gives an 























To generate the homology models of hresistin and hRELM , we first obtained 
the amino acid sequences of all the members of the resistin-like-molecule 
family. Crystal structures of mresistin (PDB code 1RFX) and mRELM  (PDB 
code 1RH7) were available[61]. I obtained a complete sequence alignment of 
all the six members of the family. I performed a BLAST searcg using the PDB 
structures of mresistin and mRELM  as templates respectively [23-31]. The 
results from BLAST revealed the sequence identity of the resistin-like 
proteins with respect to each of the templates. This allowed me to construct a 
phylogenetic tree. The phylogenetic tree determines the optional PDB 
structure to use as template to build the homology models of the rest of the 
proteins in the family. The homology models were generated using the 
SWISS-MODEL[32-35] and MODELLER[36-39] programs. SWISS-MODEL and 
MODELLER are software packages used for homology and comparative 
modelling of protein three-dimensional structure.  The first generation of 
models obtained from the programs were optimized using Rosetta Relax 
protocol to produce our final models[44+46]. The flowchart (Figure.2.1) 








Figure.2.3: The sequence alignment of all the members of the Resistin family of proteins. 
 
I next performed a BLAST analysis to determine the percentage homology 
amongst the different members and to determine the phylogenetic tree. The 
BLAST analysis determines regions of local similarity between sequences. 
This program can compare nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches. BLAST is also 
used to infer functional and evolutionary relationships between sequences. It 
also helps identify members of gene families.  The BLAST results gave me 
the percentage identity of each of the members of the resistin-like protein 
family with respective crystal structures of mresistin and mRELM  
(Table.2.1). I observed that hresistin has higher sequence identity to mresistin 
than to mRELM  as it has a 58% sequence identity whereas hRELM  is more 
homologous to mRELM  with 57% sequence identity.  
I also generated the phylogenetic tree which showed the similarity 
(Figure.2.4). The phylogenetic tree shows that mresistin and hresistin are 
more closely related to each other than to the RELM  molecules. Similarly, 




choose the templates for building the homology models. For homology 
modelling a minimum of 50 to 60 % sequence identity is required as the results 
satisfied the conditions to pursue it. Based on the sequence alignment results, 
I observed that members of this protein family are likely to have the well 
conserved jelly roll like topology. Therefore, I decided to use the mresistin 
(PDBID 1RFX) as template to model hresistin and mRELM  (PDBID 1RH7) 
to model hRELM . 
 




(hresistin) 58 49 
Human RELM-  
(hRELM ) 5β 57 
Mouse 
RELMα(mRELMα) γ8 50 
Mouse RELM-  
(mRELM ) 41 6γ 
Table.2.1: The BLAST analysis showing the percentage sequence identity of the resistin 






Figure.2.4: The phylogenetic tree of selected members of the Resistin family of protein. 
 
 
III. Building different multimeric structures 
In chapter I, resistin family proteins exist in various multimer states. 
Experimental results performed in Dr. Roger John’s laboratory revealed these 
various multimer forms of the hresistin and hRELM . A non-reducing SDS-
PAGE gel experiment was conducted by my collaborator Chunling Fan, 
where the C-terminal FLAG-tagged recombinant murine and human RELM 
proteins were overexpressed in Flp-in T-Rex 293 cells under the induction of 
tetracycline and purified with FLAG affinity chromatography. Purified 
recombinant RELMs (2-3µg/sample) mixed with non-reducing Laemmli 
loading buffer (no reducing reagents used) and were loaded onto Tris-HCl 4-
20% gradient SDS-polyacrylamide gels (Bio-Rad). After separation, the 
proteins in the gel were stained by Coomassie brilliant blue after fixation 





From the SDS-PAGE results, I concluded that hresistin and hRELM  exist in 
different multimer forms such as monomer, dimer and hexamer (Table.2.2). 
The hexamer state of the proteins are the native states of the proteins.  
 
 
Using SWISS-MODEL and MODELLER software packages, I built the first 
generation of hresistin and hRELM  structure models. I created the models 
generated as homo-trimers, mimicking the crystal states of the template PDB 
structures (Figure.2.7). The models were optimized using the Rosetta Relax 
protocol. The Relax protocol is used for simple all-atom refinement of 
structures. It is used to avoid non-ideal geometry of the protein structures. 
PROTEIN HEXAMER DIMER MONOMER 
mresistin - Native State 
On reducing and 
heating 
mRELMα - - Always 
mRELM  Native State 
On reducing form 
Trimer 
On heating and 
reducing 
mRELM  - Native State 
On heating and 
reducing 
hresistin Native State On heating 
On reducing and 
heating 
hRELM  Native State On reducing 
On heating and 
reducing 
Table.2.2: The different multimeric states of the resistin family protein summarized 








of the proteins. The helical wheel reveals the hydrophobic regions as 
diamonds, hydrophilic residues as circles, potentially negatively charged as 
triangles and potentially positively charged as pentagons. I observed that the 
helical tails of the proteins are highly hydrophobic in nature. This can 
influence the antibody-antigen docking positions. 
The hexameric forms of the proteins is visualized as the dimer of the trimer 
states of the proteins. From experimental studies, it has been observed that the 
monomeric form of the proteins are most likely to be  the functional form of 
the protein rather than its native hexamer state. Hence, for my further research 
I focused on the monomer and trimer state of the proteins. Generating a 
structural model and understanding the structural properties of the proteins is 
important for determining its binding specificities with antibodies. This aspect 















MODELLING OF THE COGNATE ANTIBODIES 
 
I. Computational Methodology 
All the antibodies that were designed by the members of the John lab, I 
computationally modelled them using the RosettaAntibody protocol[47-49]. 
This protocol predicts the three-dimensional structure of the antibody based 
on the sequences. This protocol focusses on modelling the FV region of the 
antibody as it contains the variable region that binds antigens. The FV region 
is divided into two regions -the framework and the CDR loops. The 
framework  is highly conserved and thus accurate structures of the regions are 
modelled using the template structures[47-49]. The CDR loops are known to 
have distinct structures. Five out the six loops are modelled based on the 
canonical loop conformations[47-49]. These five loops based on so called 
canonical conformations are modelled using template structures. The sixth 
loop, the CDR H3 loop does not follow any canonical conformation and must 
be modelled de-novo. As the H3 loop lies between two domains (VH and VL) 
the VH-VL orientation is also optimized in the protocol[49,50]. 
The structural model of the antibody is determined from the sequences using 
homology modelling techniques. The RosettaAntibody protocol identifies the 
CDR loop regions from the amino acid sequence and renumbers them based 
on the Chothia numbering scheme. Based on highest sequence similarity, a 
template is selected for each of the structural components- framework and 





The cognate antibodies were selected from a human antibody library by the 
members of Dr. Roger Johns’ laboratory. They had initiated an antibody 
search using hresistin or hRELM  to select SCFV binders from a phage display 
human SCFV library (Phage Display ScL-2 Library from Creative Biolabs) in 
two separate screens. 80 clones from each screen were initially chosen. 
Soluble ELISA was used to select 17 hresistin and 15 hRELM  SCFV clones 
that bound to their respective targets positively. Then additional dose related 
ELISA was performed to determine which of these antibodies was specific to 
its intended target (hresistin or hRELM ). These γβ SCFV fragments were 
subsequently made into full human IgG1 antibodies.  
I modelled each of these 32 antibodies using RosettaAntibody protocol. After 
generating the final models, I determined CDR clusters of each of the CDR 
loops of the antibodies (Table.3.1 and Table.3.2). 
 








cluster L3 cluster 
AntiRes-1 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-2 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-3 H1-13-1 H2-10-1 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-4 H1-13-1 H2-10-1 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-5 H1-13-1 H2-10-6 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-9 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-11 H1-13-1 H2-10-6 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-13 H1-13-1 H2-10-1 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 




AntiRes-17 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-18 H1-13-1 H2-10-6 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-19 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-21 H1-13-1 H2-10-1 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-24 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-26 H1-13-1 H2-10-1 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-27 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRes-41 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
Table.3.1: The CDR cluster list of 17 hresistin SCFV antibody clones 
 








cluster L3 cluster 
AntiRel-4 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-14 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-18 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-33 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-36 H1-13-1 H2-10-1 H3-9-1 L1-11-1 L2-8-1 L3-9-2 
AntiRel-38 H1-13-1 H2-10-6 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-41 H1-13-1 H2-10-2 H3-9-1 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-47 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-51 H1-13-1 H2-10-6 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-53 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-75 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 




AntiRel-22 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-28 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
AntiRel-31 H1-13-1 H2-10-2 H3-9-2 L1-11-1 L2-8-1 L3-9-cis7-1 
Table.3.2: The CDR cluster list of 15 hRELM  SCFV antibody clones 
 
Predicting the three-dimensional structure is a crucial step in improving the 
affinity, stability and suitability of these antibodies as therapeutics. The VH 
and VL domains of the antibodies are highly conserved and the CDR loops 
have small discrete set of main-chain conformations known as the canonical 
structures. These CDR clusters are based on the classification of antibody 
CDR loop conformations[51-53]. The nomenclature of the classification is 
CDR-loop length-cis/trans conformation-cluster number. I classified the 
cluster of each CDR loop using the North CDR clustering library[51-53]. This 
step was necessary, as I could check whether the templates with the most 
similarities in the sequence were used initially in the grafting step of 
RosettaAntibody protocol. In majority of the antibodies, the CDR loop 
conformations matched with the most populous CDR clusters. In a few cases 
the H2 CDR loop conformation preferred a rare CDR cluster (H2-10-6) since 
the H2 CDR loop sequence matched the consensus sequence of the cluster 
suggests that the rare cluster chosen was appropriate. 
 
III. Structural analysis of the cognate antibodies 
In experimental studies, the antibody AntiRes-13 showed the highest binding 




3, AntiRes-9, AntiRes-11 and AntiRes-41 also showed good binding affinity. 
For further discussion, I will focus on these top six antibodies.  
After I generated the final 2800 decoys, VH-VL orientation of each of the 
antibodies are checked whether they match observed distributions of the 
orientations of all the antibodies of the crystal antibody structures found in the 
PDB. I generated four plots based on the LHOC metrices which are 
interdomain distance, heavy opening angle, light opening angle and packing 
angle. Each plot shows the native distribution of VL–VH orientations (grey), 
the orientations sampled by Rosetta (black line), the top 10 models (labeled 
diamonds) and the 10 different template structures (labelled dots) used during 
grafting. From the LHOC plots of AntiRes-13 (Figure.3.2), I observed the top 
10 models were within the native distribution VH-VL orientation. Similarly, 
for antibodies AntiRes-3 (Figure.3.3), AntiRes-2, AntiRes-9, and AntiRes-11 
LHOC plots showed that my models were predicted accurately. Overall all 










ANTIBODY-ANTIGEN DOCKING RESULTS 
 
I. Overview 
Immunoprecipitation experiments showed us that the antibodies bind to 
hresistin and hRELM but the binding regions couldn’t be determined 
experimentally. To predict these binding regions and hence find the epitopes 
regions, I used ClusPro software package and RosettaSnugDock protocol. 
Using ClusPro I performed global docking to determine all possible docking 
conformations of the antibody-antigen complex[54-59]. From all the candidate 
docking conformations, I selected the top 10 poses and used them as starting 
points for local docking. To perform local docking, I used RosettaSnugDock 
protocol[60]. From RosettaSnugDock, I generated 1000 decoys for each of the 
10 starting poses. I selected the lowest energy model, by the interface energy, 
whose interface RMSD falls within a range of 10Å of the local starting 
structures. I used this lowest energy model as a reference structure and 
recalculated all the RMSDs of the rest of the decoys to the reference state. 
This allows me to view the energy surface near the reference structure to see 
if it forms an energy funnel.  This determines whether our chosen docked pose 
is the true docked state. If its not, then the steps are repeated till I determine 
the most likely docked state. After the final docked state is determined, I 
examine the putative binding site on the target antigen based on the interaction 
between the CDR loop residues and the antigen residues at the interface. 





interactions. I used the antibody mode for global docking of my antibody-
antigen systems to restrict the antibody interaction to its CDRs. ClusPro 
determines the best possible docking conformations of the antibody-antigen 
complex[59]. The top 10 docked conformations are selected. These top 10 
conformations are then used as starting points for locking docking 
calculations. 
 
III. Local Docking Results 
Using the ClusPro results as starting points, I used RosettaSnugDock protocol 
to generate 1000 decoys, for each of the top 10 docked conformations. From 
the local docking results, I plotted interface energy scores vs interface RMSD 
for all the 10,000 decoys(Figure.4.2). From the plot, I selected models which 
had the lowest interface energy within a range of 10Å interface RMSD. I used 
the lowest energy model as a reference structure docked state and recalculated 
all the RMSDs of the remaining decoys. This recalculation is a crucial step in 
determining whether the chosen lowest energy model, is the most likely 






Figure.4.3: Docking results of antibody AntiRes-13 with hresistin. The energy funnel plot 
of all the recalculated decoys based on the lowest energy model as a native structure shows 
convergence. 
 
From the plots, a good energy funnel was observed towards the reference 
structure. To check the quality of my docking results, I performed the 
bootstrap statistical analysis (N5 analysis)[62]. Bootstrap statistical analyses are 
model-independent analyses which approximate statistic variables such as 
mean, standard deviation, and test statistics without making assumptions 
about the distribution of the underlying data. From this analysis a docking 
success criteria of µ (N5) ≥β.5 and Psuccess ≥0.γ is set. My docking runs fell 
within this range with µ (N5) = 4.76 and Psuccess = 0.947 suggesting my data 
are successful and well converged. I compared the structures of the lowest 
energy models within a range of 5Å interface RMSD and -10 kcal/mol 





I repeated the same procedure for AntiRes-13 with hRELM , and determined 
the final recalculated energy funnel plot (Figure.4.5). From the plot, I 
observed that a good convergence wasn’t observed after performing the 
bootstrap statistical analysis with Psuccess = 0.21 even though my chosen native 
structure was the lowest energy model. Only the decoys similar to the lowest 




Figure.4.5: Docking results of antibody AntiRes-13 with hRELM . The energy funnel plot 
of all the recalculated decoys based on the lowest energy model as a native structure shows 
convergence of only those decoys which had same starting pose as the native structure. 
 
I determined the final docked state and its epitope region (Figure.4.6). I 
observed that AntiRes-1γ docks to the tail region of hRELM  rather than the 






The docking results of AntiRes-1γ with hRELM  contrasted with hresistin. 
This was unexpected because both hresistin and hRELM  have a strong 
homology in the head region which I had discussed in the previous chapters. 
From the docking results, I could determine that RosettaSnugDock was not 
able to determine a good docked pose. This may be due to the strong 
hydrophobic regions on the tail, and Rosetta prefers hydrophobic interactions 
between residues possibly more. Due to this the true docked state couldn’t be 
determined. 
 
When I docked AntiRes-β to hresistin and hRELM , I observed similar results 
as AntiRes-13. From the recalculated energy funnels of AntiRes-2 with 
hresistin (Figure.4.7) and hRELM (Figure.4.8), a strong convergence and 
deep energy funnel was observed in hresistin, while it wasn’t observed in 
hRELM . In case of AntiRes-β binding to hRELM , an alternate 
conformation was preferred rather than the reference structure. This is 






Figure.4.7: Docking results of antibody AntiRes-2 with hresistin. The energy funnel plot 







Figure.4.8: Docking results of antibody AntiRes-1γ with hRELM . The energy funnel plot 
of all the recalculated decoys based on the lowest energy model as a reference structure 
shows convergence of only those decoys which had same starting pose as the native 
structure. 
 
The final docked state for AntiRes-2 with both the protein were determined 
and their epitope regions calculated. AntiRes-2 docks best to the head of 
hresistin (Figure.4.9) whereas it docks best to the tail of hRELM  





Figure.4.9: Final docked state of antibody AntiRes-2 and hresistin (deep pink) 
 




When I docked AntiRes-γ with hresistin and hRELM , I observed poor 
docking funnels after the recalculation of the energy scores both in hresistin 
(Figure.4.11) and hRELM  (Figure.4.1β). I observed poor energy funnels and 
the convergence wasn’t good at all. When I determined the final docked state 
of AntiRes-γ with hresistin (Figure.4.1γ) and hRELM (Figure.4.14), the 
antibody binds to the tail regions of both the antigens. I couldn’t determine 
whether these were the likely docking positions or these positions were 
selected by Rosetta due to preference of hydrophobic interactions. 
 
Figure.4.11: Docking results for AntiRes-3 with hresistin showing energy funnel 





Figure.4.12: Docking results of AntiRes-γ with hRELM  with poor energy funnel 






Figure.4.13: Final docked state of AntiRes-3 with hresistin (deep pink) 
 






Docking antibody AntiRes-9 with hresistin and hRELM  showed positive 
results. Computationally the prediction of the final docked state for AntiRes-
9 binding with hRELM  showed much better results than hresistin. This is 
because the native structure I had chosen for recalculation had the lowest 
energy state (Figure.4.15). It also had a good energy difference with the other 
decoys also. AntiRes-9 bind to the head region for both hresistin(Figure.4.16) 
and hRELM (Figure.4.17). They bound to the same epitope regions. 
 
Figure.4.15: The energy funnel of AntiRes-9 docking with hRELM  shows the native 
structure chosen may be the true binding state as the energy gap compared with other 










Figure.4.17:The final docked state of AntiRes-9 with hRELM(salmon) 
 
Docking AntiRes-11 with hresistin and hRELM , produced the best results 
till now. The antibody docks strongly to the head region of both the proteins. 
After recalculating the energy scores, in both cases strong convergence was 
seen towards the lowest energy structure and it had a strong energy difference 
compared to the other decoys (Figure.4.18). The results suggest that 
computationally I could predict the true docked state of the antibody with the 







Figure.4.18: The docking results of AntiRes-11 with (A) hresistin and (B) hRELM  







AntiRes-9 yes  
Antires-1γ yes  
AntiRes-11 yes  
Table.4.1: Preferred docking positions of the antibodies to hresistin. 
 
monomeric hRELMβ docked with 
antibodies 
Antibody Head Tail 
AntiRes-β  yes 
AntiRes-γ  yes 
AntiRes-9 yes  
AntiRes-1γ  yes 
AntiRes-11 yes  






Table.4.3:Comparison of lowest energy models docking scores with its experimental 
results. 
Results from cell bioassay showed that antibodies AntiRes-13 and AntiRes-2 
to both antigens and block its responses. From Table.4.1, Table.4.2 and 
Table.4.3 my docking results conclude that AntiRes-13 and AntiRes-2 docks 
to hresistin strongly but not so with hRELM  as it prefers to dock to the tail 
region rather than head. As hresistin and hRELM  have very strong homology 
in the head, I expect that the antibodies should bind to similar regions in both 
the antigens. To determine this, I compared the docking results of the 
antibodies with hresistin to the docking results with hRELM . This step 
helped me to determine if there is any consensus between the binding 
locations on hresistin and hRELM . This consensus would suggest that the 
models have captured the true binding site. Comparing the docking results, I 
determined that there isn’t any consensus between the binding locations for 
both proteins (Figure.4.20). The results show that, I couldn’t capture the true 
binding regions. This is because the initial starting position for docking in 
hresistin and hRELM  are different. Both antibodies AntiRes-13 and 
AntiRes-2 showed similar outcome. This suggests that due to the hydrophobic 























AntiRes-11 + - NA NA -13.29 -11.96 
AntiRes-3 + - 20-30% 30% -11.23 -10.29 
AntiRes-9 - - 20% 10% -10.58 -13.12 
AntiRes-2 + + 30-50% 30-50% -28.67 -11.82 









In this project, I could predict preliminary structures of the monomer and 
hexamer (dimer of trimers) states of hresistin and hRELM . These modelled 
structures gave structural insight to the different states in nature. Also, I could 
successfully model all the 32 designed antibodies using RosettaAntibody. The 
modelled antibodies VH-VL orientations were within the natural structural 
parameters set by human antibodies. I could infer preliminary data of the 
different docked states of the various antibodies which experimentally bound 
to the hresistin and hRELM . In many of the cases I inferred converged results 
and could determine the epitope regions. But in some cases, there were 
discrepancies. This discrepancy in results could be caused due to preference 
of hydrophobic interactions by RosettaSnugDock or due to shape 
complementary by ClusPro. To avoid these discrepancy in the results, further 
analysis is required. This analysis could be performed by redocking the 
antibodies only to the head of the proteins, and compare the docking results. 
Removing the tail regions in the proteins will reduce the preference of 







II. Future Work 
Further work is required to successfully confirm my results. SAXS or 
crystallographic experiments can validate the predicted multimeric states of 
the proteins. The experiments will truly validate the different multimeric 
states and give better structural information of these proteins.  
To avoid the discrepancies during antibody-antigen docking, we can refine 
our docking results by targeting only the head region of the proteins as they 
have strong homology, thus avoiding the tail which has strong hydrophobic 
residues. This will help to determine whether the antibodies preferring to bind 
at the tail, truly bind in that region or are false positive results. A quantitative 
assessment of the binding structure model quality is required to distinguish 
real and false-positive binders based on number and its comparison with 
experimental data. I need to check for consensus between the binding 
locations on hresistin and hRELM , as this consensus would suggest that the 
models capture the true binding site. To improve the binding affinities to the 
target regions, we can mutate the antibody sequences. Thus, designing better 
and improved antibodies from existing data. All these analyses will give a 
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    Equipment Used    : FTIR spectroscopy, SEM, DSC, TGA     
     
b. Title of the project : Cloning, purification and crystallization of the protein Tear GD1 from 
Thermotoga maritima to determine its 3D structure using X- ray diffraction technique.     
    Duration          : 1st June, 2013 to 6th August, 2013     
    Institute          : Indian Institute of Technology Kanpur, Kanpur, U.P      
Name of Supervisor : Prof. Balaji Prakash (bprakash@iitk.ac.in)     
              Equipment Used       : AKTA (for purification purpose), PCR Thermocycle setup,     
Mosquito (for crystallization)     
     
c. Title of the project: Characterization and synthesis of Graphene using Chemical Vapor 
Deposition method.     
    Duration         : 20st June, 2013 to 6th August, 2013     
       Institute     : Indian Institute of Technology Kanpur, Kanpur, U.P      
Name of Supervisor : Prof. Kamal K. Kar (kamalkk@iitk.ac.in)     
   Equipment Used    : Raman spectroscopy, AFM (atomic forced microscopy), DSC, TGA     
     
d. Title of the project: Rheology analysis of Polyacrylamide                           
Duration                     : 16th December 2013 to 13th January 2014     
            Institute                      : Indian Institute of Technology Kanpur, Kanpur, 
U.P   Name of Supervisor  :Prof. Yogesh M. Joshi(joshi@iitk.ac.in)                        
Equipment Used       : Rheometer     
          




            Duration                     : 28th May 2014 to 1st August 2014     
            Institute                      : Technische Universität München, München, Germany     
            Name of Supervisor   : Prof. Dr.-Ing. Habil. Andreas 
Kremling(a.kremling@lrz.tumuenchen.de)     
                      
14. Paper Published/Accepted:     
     
• Weitzner BD, Jeliazkov JR, Lyskov S, Marze N, Kuroda D, Frick R, Adolf-Bryfogle A,     
          Biswas N & Gray JJ "Modeling and docking antibody structures with Rosetta,"  Nature 
Protocols 12, 401–416 (2017)     
     
• N. Gomathi, L. G. Nair, J. Lavanya, N. Biswas, K. Joseph, C. P. Reghunadhan Nair, S. Neogi, 
RF plasma method - a straightforward, dry means for functionalization of carbon 
nanotubes , a epted for prese tatio  i  International Symposium on Plasma 
Chemistry, Cairns, Australia, 4-9th  August, 2013     
   
Curre tl  i  the pro ess of riti g a paper ased o   Master’s thesis ork. This paper ill 
include my work on structural modeling of Resistin proteins with its cognate antibodies to 
develop potential therapeutics for Pulmonary Hypertension.    
     
15. Review Paper Presented:     
     
• Naireeta Biswas, D. Neha Redd , Milking of diatoms for the generation of biodiesel  
in the event Chemignite organized by Indian Institute of Chemical Engineers (IIChE) 
Student Chapter Manipal, Manipal University, September, 2012.     
     
16. Poster Presentation:     
• Prese ted a poster o   Structural modelling of Resistin and RELM family proteins 
and their cognate antibodies   at the Che BE re ruit e t eeke d held o  Mar h 
18th , 2016      
     
17. Conferences Attended:     
• Attended the Winter’s RosettaCon held at San Diego, California from February 7th 




• Attended the Grace Hopper Celebration for Women in Computing held at 
Houston, Texas from October 18th to October 22nd, 2016     
• Attended the annual IBR Retreat organized by the Bio-Physics Department of Johns 
Hopkins  University.     
     
18. Teaching Experience:     
• Teaching Assistant for the undergraduate course Chemical Engineering Lab for the fall 
2015      
• Part of the STEM Achievement in Baltimore Elementary Schools (SABES) program 
mentoring 4th grade students once a week      
• Mentoring undergraduate student Shuheng (Kathy) Wang, a member of the Gray Lab      
     
19. Extra-Curricular Activity:     
     
• Member of the Rosetta Commons as a developer     
• Member of the Working committee of IIChE, Student Chapter of Manipal Branch.     
• Member of the organizing committee of CHEMOTHON organized by IIChE, India 
as the part of Technical festival at MIT, Manipal.      
• North zone champion in inter-CBSE school meet in swimming in 2005,2004     
• Participated national level CBSE board swimming championship in 2005.     
• Passed with distinction up to 3rd year in Violin from Akhil Bharatiya Gandharv 
Mahavidyalaya.     
• Enjoy painting and sketching and received prizes in local competition.     
• Me er of the orga izi g o ittee of PANORAMA a ultural festi al orga ized 
by Delhi Public School, Kalyanpur, Kanpur.     
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